PRESS RELEASE published on 10/20/2025 at 13:30, 11 months ago Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program Sanofi's Tzield accepted for expedited review by FDA under National Priority Voucher pilot program to delay progression of stage 3 type 1 diabetes. Breakthrough therapy with significant unmet medical need addressed FDA Sanofi Type 1 Diabetes Tzield National Priority Voucher
PRESS RELEASE published on 10/20/2025 at 13:30, 11 months ago Communiqué de presse : L’autorisation de Sanofi pour Tzield a été acceptée aux États-Unis pour le diabète de type 1 de stade 3 dans le cadre du programme pilote du voucher national de priorité du Commissaire de la FDA La FDA accepte l'examen de Tzield pour le diabète de type 1 de stade 3 aux États-Unis dans le cadre du programme piloté du voucher national de priorité du Commissaire, offrant un potentiel de traitement novateur FDA Autorisation Diabète De Type 1 Tzield Traitement Novateur
BRIEF published on 10/20/2025 at 08:35, 11 months ago Sanofi's AlphaMedix Shows Promise in Treating GEP-NETs Phase 2 Study Sanofi AlphaMedix GEP-NETs Targeted Alpha Therapy
BRIEF published on 10/20/2025 at 08:35, 11 months ago AlphaMedix de Sanofi se révèle prometteur dans le traitement des TNE-GEP Étude De Phase 2 Sanofi AlphaMedix GEP-NET Thérapie Alpha Ciblée
PRESS RELEASE published on 10/20/2025 at 08:30, 11 months ago Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...) Les nouvelles données de l'essai de phase 2 ALPHAMEDIX-02 soulignent le potentiel thérapeutique prometteur d'AlphaMedix™ pour les tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP), avec des réponses prolongées et significatives chez les patients Essai De Phase 2 AlphaMedix Potentiel Thérapeutique TNE-GEP Alphathérapie
PRESS RELEASE published on 10/20/2025 at 08:30, 11 months ago Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New phase 2 data presented at ESMO Congress highlight AlphaMedix as a promising targeted alpha therapy for GEP-NETs, showing high response rates and potential to address unmet medical needs ESMO Congress AlphaMedix Phase 2 Data GEP-NETs Targeted Alpha Therapy
BRIEF published on 10/20/2025 at 07:05, 11 months ago Sanofi's High-Dose Flu Vaccine Shows Enhanced Protection for Seniors Sanofi Flu Vaccine Senior Health Hospitalization Reduction FLUNITY-HD Study
BRIEF published on 10/20/2025 at 07:05, 11 months ago Le vaccin antigrippal à haute dose de Sanofi offre une protection renforcée aux personnes âgées Sanofi Vaccin Contre La Grippe Réduction Des Hospitalisations Santé Des Personnes Âgées Étude FLUNITY-HD
PRESS RELEASE published on 10/20/2025 at 07:00, 11 months ago Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les seniors par rapport aux vaccins à dose standard Efficacité Sanofi Seniors Hospitalisations Vaccin Antigrippal
PRESS RELEASE published on 10/20/2025 at 07:00, 11 months ago Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Sanofi's high-dose influenza vaccine Efluelda/Fluzone High-Dose shows superior protection for older adults by reducing hospitalizations. FLUNITY-HD study details robust evidence published in The Lancet Older Adults Sanofi Influenza Vaccine FLUNITY-HD Study Hospitalizations
Published on 09/19/2026 at 00:55, 1 day 13 hours ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 22:00, 1 day 15 hours ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 1 day 17 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 23 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/20/2026 at 09:05, 4 hours 54 minutes ago Huawei Digital Power Showcases Multi-Scenario Solutions Featuring Grid Forming and AI at IDEE 2026
Published on 09/20/2026 at 06:30, 7 hours 29 minutes ago Huawei Grid-Interactive AIDC Solution: Shaping the New Paradigm of AI Infrastructure
Published on 09/20/2026 at 04:35, 9 hours 24 minutes ago How to Achieve Sustainable Power Without Changing Your Existing Backup System
Published on 09/19/2026 at 16:40, 21 hours 19 minutes ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/19/2026 at 13:15, 1 day ago Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/18/2026 at 18:34, 1 day 19 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 18:34, 1 day 19 hours ago Déclaration hebdomadaire d'opérations effectuées du 14 au 18 septembre 2026
Published on 09/18/2026 at 17:45, 1 day 20 hours ago Communiqué de presse_Carrefour Bond_Septembre 2026